PfizerPFEEarnings & Financial Report
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. Founded in 1849 in New York by German entrepreneurs Charles Pfizer (1824–1906) and Charles F. Erhart (1821–1891), Pfizer is one of the oldest pharmaceutical companies in North America.
Revenue
$13.3B
Gross Profit
$10.0B
Operating Profit
$-103.0M
Net Profit
$41.0M
Gross Margin
75.2%
Operating Margin
-0.8%
Net Margin
0.3%
YoY Growth
-27.3%
EPS
$0.01
Pfizer Q2 FY2024 Financial Summary
Pfizer reported revenue of $13.3B (down 27.3% YoY) for Q2 FY2024, with a net profit of $41.0M (down 99.3% YoY) (0.3% margin). Cost of goods sold was $3.3B, operating expenses totaled $10.1B.
Key Financial Metrics
| Total Revenue | $13.3B |
|---|---|
| Net Profit | $41.0M |
| Gross Margin | 75.2% |
| Operating Margin | -0.8% |
| Report Period | Q2 FY2024 |
Revenue Breakdown
Pfizer Q2 FY2024 revenue of $13.3B breaks down across 6 segments, led by Specialty Care at $4.1B (30.7% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Specialty Care | $4.1B | 30.7% |
| Oncology | $4.0B | 29.8% |
| Oncology Division | $2.9B | 22.0% |
| Total Alliance Biopharmaceuticals | $2.1B | 15.6% |
| Royalty | $345.0M | 2.6% |
| Pfizer Ignite | $15.0M | 0.1% |
Pfizer Revenue by Segment — Quarterly Trend
Pfizer revenue by segment across the last 4 reported quarters, showing how each business line (such as Specialty Care and Oncology) has evolved quarter over quarter.
| Segment | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 |
|---|---|---|---|---|
| Specialty Care | — | $4.8B | — | — |
| Total Alliance Biopharmaceuticals | — | $2.6B | $2.3B | $2.3B |
| Royalty | — | $480.0M | $436.0M | $426.0M |
Pfizer Annual Revenue by Year
Pfizer annual revenue history includes year-by-year totals (for example, 2025 revenue was $62.6B).
| Year | Annual Revenue |
|---|---|
| 2025 | $62.6B |
| 2024 | $63.6B |
Pfizer Quarterly Revenue & Net Profit History
Pfizer results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $14.5B | +5.0% | $2.7B | 18.6% |
| Q4 FY2025 | $17.6B | -1.2% | $-1.6B | -9.4% |
| Q3 FY2025 | $16.7B | -5.9% | $3.5B | 21.3% |
| Q2 FY2025 | $14.7B | +10.3% | $2.9B | 19.9% |
| Q1 FY2025 | $13.7B | -7.8% | $3.0B | 21.6% |
| Q4 FY2024 | $17.8B | +34.2% | $410.0M | 2.3% |
| Q3 FY2024 | $17.7B | +39.0% | $4.5B | 25.2% |
| Q2 FY2024 | $13.3B | -27.3% | $41.0M | 0.3% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $13.28B | $17.70B | $17.76B | $13.71B | $14.65B | $16.65B | $17.56B | $14.45B |
| YoY Growth | -27.3% | 39.0% | 34.2% | -7.8% | 10.3% | -5.9% | -1.2% | 5.0% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $216.19B | $219.48B | $213.40B | $208.03B | $206.09B | $208.73B | $208.16B | N/A |
| Liabilities | $128.22B | $126.92B | $124.90B | $117.39B | $117.08B | $115.64B | $121.39B | N/A |
| Equity | $87.70B | $92.29B | $88.20B | $90.34B | $88.69B | $92.80B | $86.48B | N/A |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $-1.78B | $6.71B | $6.72B | $2.33B | $-582.0M | $4.60B | $5.35B |